(Empagliflozin + metformin + sitagliptin) is under clinical development by Chong Kun Dang Pharmaceutical and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Empagliflozin + metformin + sitagliptin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Empagliflozin + metformin + sitagliptin) overview

The fixed dose combination of empagliflozin, metformin, and sitagliptin is under development for the treatment of type 2 diabetes. It is administered through oral route as tablets. Empagliflozin acts by targeting sodium-glucose co-transporter 2 (SGLT2), metformin targets AMP-activated protein kinase (AMPK) and sitagliptin targets dipeptidyl-peptidase (DPP-4).

Chong Kun Dang Pharmaceutical overview

Chong Kun Dang Pharmaceutical Corp (CKD Pharma), manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company works following therapeutic areas such as oncology, neurology and immunology and others. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colours; aerosols; mat vaporizers and mosquito coils; and others. The company’s Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs, The Technology Development Labs; and the Bio Research Labs. It has a manufacturing facility in Cheonan City, South Korea. CKD Pharma is headquartered in Seoul, South Korea.

For a complete picture of (Empagliflozin + metformin + sitagliptin)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.